Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftazidime-avibactam vs meropenem for nosocomial pneumonia including ventilator-associated pneumonia in adults
jRCT2080222278Phase 3
- Sponsor
- AstraZeneca
- Start
- Nov 2013
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceftazidime + avibactam in hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (2 arms), sponsored by AstraZeneca.
02
Drugs
ceftazidime + avibactam
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on jRCT2080222278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222278.